We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
miR-128-3p serves as an oncogenic microRNA in osteosarcoma cells by downregulating ZC3H12D.
- Authors
MAOSHU ZHU; YULONG WU; ZHAOWEI WANG; MINGHUA LIN; BIN SU; CHUNYANG LI; FULONG LIANG; XINJIANG CHEN
- Abstract
Osteosarcoma is the second leading cause of cancer-associated mortality worldwide in children and adolescents. ZC3H12D has been shown to negatively regulate Toll-like receptor signaling and serves as a possible tumor suppressor gene. MicroRNAs (miRNAs/miRs) are known to play an important role in the proliferation of human osteosarcoma cells. However, whether miRNAs can affect tumor development by regulating the expression of ZC3H12D has not yet been investigated. The aim of the present study was to investigate the role of miR128-3p in regulating ZC3H12D expression, as well as its function in tumor cell proliferation, apoptosis, and metastasis. Reverse transcription-quantitative PCR, western blotting and dual luciferase reporter assays were performed to analyze the regulation of ZC3H12D expression by miR-128-3p. MTT, colony formation and flow cytometry assays were also used to analyze the effect of miR-128-3p on cell proliferation and apoptosis. A wound healing assay was performed to investigate the cell migration ability. The results demonstrated that miR-128-3p directly targeted ZC3H12D and downregulated its expression, thereby promoting cell proliferation and migration. miR-128-3p overexpression also improved resistance to cisplatin in MG-63 and 143B cell lines, supporting the hypothesis that miR-128-3p may function as an oncogene in osteosarcoma cells. The potential clinical significance of miR-128-3p as a biomarker and therapeutic target provides rationale for further investigation into the miR-128-3p-mediated molecular pathway and how it is associated with osteosarcoma development.
- Subjects
OSTEOSARCOMA; TUMOR suppressor genes; CELL migration; MICRORNA; TOLL-like receptors
- Publication
Oncology Letters, 2021, Vol 21, Issue 2, p1
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2020.12413